title: After the London tragedy, is it still possible to consider Phase I is safe?
authors.forename: Michel
authors.initials: M
authors.lastname: Sibille
authors.forename: Yves
authors.initials: Y
authors.lastname: Donazzolo
authors.forename: Franck
authors.initials: F
authors.lastname: Lecoz
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Krupka
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic / Q000401:mortality*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000494:pharmacology; D018570:Risk Assessment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; C509303:TGN-1412